Mostly positive, with trade-offs people accept. In 120 adults on tirzepatide, 91.7% reported losing weight [3]. Stomach side effects were usually mild and passed. Less hunger and quieter food thoughts are the first theme in patient interviews [1]. The measured side of that is in whether GLP-1 drugs reduce food noise.
This evidence is what patients say. It is not trial data. Interviews show what happens, not how often.
What four studies asked
One team interviewed adults across 15 US states (n = 30) [1]. 23 were on a GLP-1 at the time. 7 had stopped.
A second team read 660 posts from a Wegovy forum on Reddit [2]. The posts ran from October 2022 to October 2023.
A third surveyed adults on tirzepatide (n = 120), then interviewed 15 [3]. 85.8% had used it for under six months.
A fourth surveyed 1,659 people managed in a virtual setting [4]. Some also kept video diaries.
Appetite comes up first
The first theme in the 30 interviews was reduced food noise, hunger or appetite. The 1,659-person survey reported the same. Participants said the drugs cut food thoughts and improved fullness.
On the forum, efficacy was the biggest topic. It took 29.4% of coded posts. How weight loss felt took 22.8%.
Tirzepatide interviewees described high satisfaction. They also named better sleep, energy, mood and confidence.
Side effects, and what people tolerate
Managing side effects took 13.3% of forum posts. In the tirzepatide interviews, stomach effects were usually mild and transient.
The 30 interviews add a harder point. People said they would withstand substantial side effects and logistics to keep losing weight.
That tolerance cuts both ways. It can keep people on the drug. It can also keep them with a poor service. The full list of effects is in the side effects of a GLP-1.
Support varies by prescriber
The 30 interviews named clinical support as essential and highly variable. The authors ask for standard patient education guidelines.
In practice, two sellers at similar prices can deliver different amounts of care. What a coach adds is in whether you need a coach with a GLP-1.
Patients also called the drug a facilitator, not a replacement, for lifestyle change. The 1,659-person survey found both patterns. Some changed habits. Others relied mainly on the drug.
Cost, stigma, and stopping
Cost and access came up as prohibitive in the interviews. Access took 10.7% of forum posts. Tirzepatide users with insurance scored higher on eating self-efficacy than those paying themselves.
Stigma varied with why the drug was prescribed. It took 4.4% of forum posts. That thread is in whether people judge you for taking a GLP-1.
In the 1,659-person survey, people stopped over cost, unmet expectations and side effects. 55% had tried to lose weight for over ten years first. The reasons are ranked in why people stop taking a GLP-1.
The price is the part a buyer can check before starting. The monthly figures are in what a GLP-1 costs per month.